These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 17065430)

  • 1. Allele-specific polymerase chain reaction for the imatinib-resistant KIT D816V and D816F mutations in mastocytosis and acute myelogenous leukemia.
    Corless CL; Harrell P; Lacouture M; Bainbridge T; Le C; Gatter K; White C; Granter S; Heinrich MC
    J Mol Diagn; 2006 Nov; 8(5):604-12. PubMed ID: 17065430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis.
    Erben P; Schwaab J; Metzgeroth G; Horny HP; Jawhar M; Sotlar K; Fabarius A; Teichmann M; Schneider S; Ernst T; Müller MC; Giehl M; Marx A; Hartmann K; Hochhaus A; Hofmann WK; Cross NC; Reiter A
    Ann Hematol; 2014 Jan; 93(1):81-8. PubMed ID: 24281161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutically relevant mutations in the receptor tyrosine kinase KIT in mastocytosis].
    Sotlar K
    Verh Dtsch Ges Pathol; 2007; 91():169-76. PubMed ID: 18314612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR.
    Schumacher JA; Elenitoba-Johnson KS; Lim MS
    J Clin Pathol; 2008 Jan; 61(1):109-14. PubMed ID: 17526803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.
    Ustun C; Corless CL; Savage N; Fiskus W; Manaloor E; Heinrich MC; Lewis G; Ramalingam P; Kepten I; Jillella A; Bhalla K
    Leuk Res; 2009 May; 33(5):735-41. PubMed ID: 18986703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
    Kang HY; Hwang JY; Kim SH; Goh HG; Kim M; Kim DW
    Haematologica; 2006 May; 91(5):659-62. PubMed ID: 16627254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A; Sonneck K; Gleixner KV; Schuch K; Pickl WF; Blatt K; Peter B; Herrmann H; Schernthaner GH; Pehamberger H; Rabitsch W; Sperr WR; Valent P
    Exp Hematol; 2010 Sep; 38(9):744-55. PubMed ID: 20553795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.
    Bougherara H; Georgin-Lavialle S; Damaj G; Launay JM; Lhermitte L; Auclair C; Arock M; Dubreuil P; Hermine O; Poul MA
    Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):62-9. PubMed ID: 23127495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations KITD816V and JAK2V617F.
    Sotlar K; Bache A; Stellmacher F; Bültmann B; Valent P; Horny HP
    J Mol Diagn; 2008 Jan; 10(1):58-66. PubMed ID: 18165278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis, clinical features, and treatment advances in mastocytosis.
    Pardanani A; Akin C; Valent P
    Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tryptase correlates with the KIT D816V mutation burden in adults with indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2013 Aug; 91(2):106-11. PubMed ID: 23621866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive detection of KIT D816V in patients with mastocytosis.
    Tan A; Westerman D; McArthur GA; Lynch K; Waring P; Dobrovic A
    Clin Chem; 2006 Dec; 52(12):2250-7. PubMed ID: 17040960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mastocytosis: advances in diagnosis and treatment.
    Hungness SI; Akin C
    Curr Allergy Asthma Rep; 2007 Jul; 7(4):248-54. PubMed ID: 17547845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.
    Ustun C; DeRemer DL; Akin C
    Leuk Res; 2011 Sep; 35(9):1143-52. PubMed ID: 21641642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Digital PCR: A Sensitive and Precise Method for
    Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Simonitsch-Klupp I; Mitterbauer-Hohendanner G; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
    Clin Chem; 2018 Mar; 64(3):547-555. PubMed ID: 29237714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
    Pan J; Quintás-Cardama A; Kantarjian HM; Akin C; Manshouri T; Lamb P; Cortes JE; Tefferi A; Giles FJ; Verstovsek S
    Blood; 2007 Jan; 109(1):315-22. PubMed ID: 16912224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of the KIT
    Craig JW; Hasserjian RP; Kim AS; Aster JC; Pinkus GS; Hornick JL; Steensma DP; Coleman Lindsley R; DeAngelo DJ; Morgan EA
    Mod Pathol; 2020 Jun; 33(6):1135-1145. PubMed ID: 31896808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.
    Zhang LY; Smith ML; Schultheis B; Fitzgibbon J; Lister TA; Melo JV; Cross NC; Cavenagh JD
    Leuk Res; 2006 Apr; 30(4):373-8. PubMed ID: 16183119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.